-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $50

Benzinga·06/16/2025 15:21:39
Listen to the news
Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $125 to $50.